Statement: Cohort 1 of the primary trial and Cohort 1 of the secondary trial  have the same total number of adverse events.
Primary_evidence: Adverse Events 1:   Total: 15/52 (28.85%)   Anaemia * 1/52 (1.92%)   Febrile neutropenia 24/52 (7.69%)   Neutropenia 28/52 (15.38%)   Cardiac failure chronic 21/52 (1.92%)   Vomiting 23/52 (5.77%)   Diarrhoea 21/52 (1.92%)   Gastric ulcer 21/52 (1.92%)   Gastritis 21/52 (1.92%)   Nausea 21/52 (1.92%)   Fatigue 21/52 (1.92%)   Pyrexia 21/52 (1.92%)   Gastroenteritis 21/52 (1.92%)
Secondary_evidence: Adverse Events 1:   Total: 2/7 (28.57%)   Anaemia * 0/7 (0.00%)   Iron Deficiency Anaemia * 0/7 (0.00%)   Pericardial Effusion * 0/7 (0.00%)   Adrenal Insufficiency * 1/7 (14.29%)   Abdominal Pain * 0/7 (0.00%)   Gastritis Erosive * 0/7 (0.00%)   Urosepsis * 0/7 (0.00%)   Pneumonia * 0/7 (0.00%)   Urinary Tract Infection * 0/7 (0.00%)   Enterocolitis infectious * 0/7 (0.00%) Adverse Events 2:   Total: 1/8 (12.50%)   Anaemia * 1/8 (12.50%)   Iron Deficiency Anaemia * 0/8 (0.00%)   Pericardial Effusion * 0/8 (0.00%)   Adrenal Insufficiency * 0/8 (0.00%)   Abdominal Pain * 0/8 (0.00%)   Gastritis Erosive * 0/8 (0.00%)   Urosepsis * 0/8 (0.00%)   Pneumonia * 0/8 (0.00%)   Urinary Tract Infection * 0/8 (0.00%)   Enterocolitis infectious * 0/8 (0.00%)